Centene (CNC) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Centene (CNC) has outperformed Illumina (ILMN) over the past year, gaining 74.7% versus a gain of 55.7%. Over five years, CNC leads with a -13.7% price change compared with -46.4% for ILMN. Centene is the larger company by market cap ($31.58 billion vs $29.15 billion), about 1.1 times the size.
On valuation, Centene trades at a lower forward P/E (11.4x vs 31.2x for Illumina). Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -3.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNC | ILMN |
|---|---|---|
| Share price | $63.78 | $192.82 |
| Market cap | $31.58B | $29.15B |
| 1-day change | -2.74% | -3.90% |
| YTD return | +54.99% | +47.01% |
| 1-year return | +74.74% | +55.69% |
| 5-year return | -13.69% | -46.40% |
| P/E ratio (TTM) | 21.92 | 33.19 |
| Forward P/E | 11.45 | 31.19 |
| EPS (TTM) | $2.91 | $5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $194.78B | $4.34B |
| Revenue growth (YoY) | +19.44% | -0.66% |
| Net income (latest FY) | $-6.67B | $850.00M |
| Gross margin | 7.30% | 66.08% |
| Operating margin | -3.91% | 18.58% |
| Net margin | -3.43% | 19.57% |
| 52-week high | $78.08 | $309.35 |
| 52-week low | $31.63 | $112.65 |
| Distance from 52-week high | -18.31% | -37.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +19.33% | +35.59% |
| Average volume | 5.09M | 2.82M |
| Shares outstanding | 495.07M | 151.20M |
| Employees | 61,100 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNC has outperformed ILMN by 19.1 percentage points over the past year.
- Illumina trades at a higher earnings multiple (33.2x vs 21.9x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -3.4 cents for Centene.
- Centene grew revenue faster in its latest fiscal year (+19.44% vs -0.66%).
About Centene
CNC stock →Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.
Health Care · Medical Specialities · 61,100 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
CNC vs ILMN FAQ
Which is bigger, Centene or Illumina?
Centene (CNC) is larger, with a market capitalization of $31.58B compared with $29.15B for Illumina (ILMN).
Which stock has performed better over the past year, CNC or ILMN?
CNC returned +74.74% over the past 12 months, compared with +55.69% for ILMN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CNC or ILMN?
CNC has the lower trailing P/E at 21.9, versus 33.2 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Centene and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.